tbuckley/cabot-search huggingface dataset:
Neutrophil extracellular traps protect the kidney from ascending infection and are required for a positive leukocyte dipstick test
Authors: Andrew P. Stewart, Kevin W. Loudon, Matthew Routledge, Colin Y. C. Lee, Patrick Trotter, Nathan Richoz, Eleanor Gillman, Robin Antrobus, James Mccaffrey, David Posner, Andrew Conway Morris, Fiona E. Karet Frankl, Menna R. Clatworthy
Journal: Science Translational Medicine (2024)

Lower urinary tract infection (UTI) is common but only rarely complicated by pyelonephritis. However, the mechanisms preventing extension to the kidney are unclear. Here, we identified neutrophil extracellular traps (NETs) in healthy human urine that provide an antibacterial defense strategy within the urinary tract. In both in vivo murine models of UTI where uropathogenic E. coli are inoculated into the bladder and ex vivo human urine models, NETs interacted with uromodulin to form large webs that entrapped the bacteria. Peptidyl arginine deiminase 4 (PADI4) inhibition in mice blocked NETosis and resulted in progression of cystitis into pyelonephritis, suggesting that NETosis of urinary neutrophils acts to prevent bacterial ascent into the kidney. Analysis of UK Biobank data revealed that genetic variants in PADI4 that associated with increased risk of rheumatoid arthritis in multiple genome-wide association studies were consistently associated with reduced susceptibility to UTI. Last, we showed that urine dipstick testing for leukocyte esterase was negative in the presence of intact blood neutrophils but became positive when neutrophils were stimulated to NET, and this could be prevented by selective PADI4 inhibition, demonstrating that this test does not detect absolute neutrophil count, as has long been assumed, but specifically detects neutrophils that have undergone NETosis. These findings highlight the role of NETosis in preventing ascending infections in the urinary tract and improve our understanding of one of the most common clinical tests in medicine.
Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection
Authors: Shunying Zhao, Yunxiao Shang, Yong Yin, Yingxue Zou, Yongsheng Xu, Lili Zhong, Hailin Zhang, Hua Zhang, Deyu Zhao, Tong Shen, Dongming Huang, Qiang Chen, Qiaozhi Yang, Yungang Yang, Xiaoyan Dong, Ling Li, Zhimin Chen, Enmei Liu, Li Deng, Wenhui Jiang, Huanji Cheng, Guangmin Nong, Xiufang Wang, Yiping Chen, Rong Ding, Wei Zhou, Yuejie Zheng, Zhaobo Shen, Xiaoxia Lu, Chuangli Hao, Xiaoping Zhu, Tan Jia, Yan Wu, Gang Zou, Ki Rito, Jim Z. Wu, Hanmin Liu, Xin Ni
Journal: New England Journal of Medicine (2024)

Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the treatment of infants hospitalized with RSV infection.
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B
Authors: Adam Cuker, Kaan Kavakli, Laurent Frenzel, Jiaan-Der Wang, Jan Astermark, Monica H. Cerqueira, Alfonso Iorio, Olga Katsarou-Fasouli, Robert Klamroth, Amy D. Shapiro, Cédric Hermans, Akira Ishiguro, Andrew D. Leavitt, Johannes B. Oldenburg, Margareth C. Ozelo, Jerome Teitel, Francesca Biondo, Annie Fang, Joanne Fuiman, John McKay, Pengling Sun, John E.J. Rasko, Jeremy Rupon
Journal: New England Journal of Medicine (2024)

Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia B containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua), was associated with sustained factor IX activity in a phase 1-2a study.
New criteria for estimating numbers of CD34-positive cells in a graft needed for posttransplant bone marrow recovery
Authors: Yahui Feng, Saibing Qi, Yu Hu, Wen Yan, Yanping Ji, Mingyang Wang, Xiaowen Gong, Qiujin Shen, Wei Zhang, Huilan Liu, Xianjing Zhang, Mengyun Chen, Erling Chen, Xiaolin Zhai, Yi He, Donglin Yang, Aiming Pang, Mingzhe Han, Robert Peter Gale, Zimin Sun, Erlie Jiang, Junren Chen
Journal: Leukemia (2024)
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
Authors: Bruce E. Sands, Brian G. Feagan, Laurent Peyrin-Biroulet, Silvio Danese, David T. Rubin, Olivier Laurent, Allison Luo, Deanna D. Nguyen, Jiandong Lu, Mark Yen, Jaroslaw Leszczyszyn, Radosław Kempiński, Dermot P.B. McGovern, Christopher Ma, Timothy E. Ritter, Stephan Targan
Journal: New England Journal of Medicine (2024)

Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis. A genetic-based diagnostic test was designed to identify patients with an increased likelihood of response.
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma
Authors: Farhad Ravandi, Jayastu Senapati, Nitin Jain, Nicholas J Short, Tapan Kadia, Gautam Borthakur, Marina Konopleva, William Wierda, Xuelin Huang, Abhishek Maiti, Ghayas Issa, Hayley Balkin, Rebecca Garris, Alessandra Ferrajoli, Guillermo Garcia-Manero, Yesid Alvarado, Partow Kebriaei, Elias Jabbour, Hagop M Kantarjian
Journal: Leukemia (2024)
MERTK inhibition selectively activates a DC – T-cell axis to provide anti-leukemia immunity
Authors: Justus M Huelse, Swati S Bhasin, Kristen M Jacobsen, Juhye Yim, Beena E Thomas, Gianna M Branella, Mojtaba Bakhtiari, Madison L Chimenti, Travon A Baxter, Sunil S Raikar, Xiaodong Wang, Stephen V Frye, Curtis J Henry, H Shelton Earp, Manoj Bhasin, Deborah DeRyckere, Douglas K Graham
Journal: Leukemia (2024)
Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy
Authors: Xinchen Lu, Jinmei Jin, Ye Wu, Jiayi Lin, Xiaokun Zhang, Shengxin Lu, Jiyuan Zhang, Chunling Zhang, Maomao Ren, Hongzhuan Chen, Weidong Zhang, Xin Luan
Journal: Bioactive Materials (2024)
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma
Authors: Laura Martinez-Verbo, Yoana Veselinova, Pere Llinàs-Arias, Carlos A García-Prieto, Aleix Noguera-Castells, Miguel L Pato, Alberto Bueno-Costa, Ignacio Campillo-Marcos, Lorea Villanueva, Aina Oliver-Caldes, Oriol Cardus, Sergi V Salsench, Almudena García-Ortiz, Antonio Valeri, Elizabeta A Rojas, Naroa Barrena, Norma C Gutiérrez, Felipe Prósper, Xabier Agirre, Carlos Fernández de Larrea, Joaquín Martínez-López, Gerardo Ferrer, Manel Esteller
Journal: Leukemia (2024)
Results after Four Years of Screening for Prostate Cancer with PSA and MRI
Authors: Jonas Hugosson, Rebecka Arnsrud Godtman, Jonas Wallstrom, Ulrika Axcrona, Anders Bergh, Lars Egevad, Kjell Geterud, Ali Khatami, Andreas Socratous, Vasiliki Spyratou, Linda Svensson, Johan Stranne, Marianne Månsson, Mikael Hellstrom
Journal: New England Journal of Medicine (2024)

Data on the efficacy and safety of screening for prostate cancer with magnetic resonance imaging (MRI) are needed from studies of follow-up screening.
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
Authors: Edo Kapetanovic, Cédric R Weber, Marine Bruand, Daniel Pöschl, Jakub Kucharczyk, Elisabeth Hirth, Claudius Dietsche, Riyaz Khan, Bastian Wagner, Olivier Belli, Rodrigo Vazquez-Lombardi, Rocío Castellanos-Rueda, Raphael B Di Roberto, Kevin Kalinka, Luca Raess, Kevin Ly, Shivam Rai, Petra S Dittrich, Randall J Platt, Elisa Oricchio, Sai T Reddy
Journal: Nature Biomedical Engineering (2024)

Abstract Bispecific antibodies (biAbs) used in cancer immunotherapies rely on functional autologous T cells, which are often damaged and depleted in patients with haematological malignancies and in other immunocompromised patients. The adoptive transfer of allogeneic T cells from healthy donors can enhance the efficacy of biAbs, but donor T cells binding to host-cell antigens cause an unwanted alloreactive response. Here we show that allogeneic T cells engineered with a T-cell receptor that does not convert antigen binding into cluster of differentiation 3 (CD3) signalling decouples antigen-mediated T-cell activation from T-cell cytotoxicity while preserving the surface expression of the T-cell-receptor–CD3 signalling complex as well as biAb-mediated CD3 signalling and T-cell activation. In mice with CD19 + tumour xenografts, treatment with the engineered human cells in combination with blinatumomab (a clinically approved biAb) led to the recognition and clearance of tumour cells in the absence of detectable alloreactivity. Our findings support the development of immunotherapies combining biAbs and ‘off-the-shelf’ allogeneic T cells.
Yield of genetic association signals from genomes, exomes and imputation in the UK Biobank
Authors: Sheila M Gaynor, Tyler Joseph, Xiaodong Bai, Yuxin Zou, Boris Boutkov, Evan K Maxwell, Olivier Delaneau, Robin J Hofmeister, Olga Krasheninina, Suganthi Balasubramanian, Anthony Marcketta, Joshua Backman, Jeffrey G Reid, John D Overton, Luca A Lotta, Jonathan Marchini, William J Salerno, Aris Baras, Goncalo R Abecasis, Timothy A Thornton
Journal: Nature Genetics (2024)

Abstract Whole-genome sequencing (WGS), whole-exome sequencing (WES) and array genotyping with imputation (IMP) are common strategies for assessing genetic variation and its association with medically relevant phenotypes. To date, there has been no systematic empirical assessment of the yield of these approaches when applied to hundreds of thousands of samples to enable the discovery of complex trait genetic signals. Using data for 100 complex traits from 149,195 individuals in the UK Biobank, we systematically compare the relative yield of these strategies in genetic association studies. We find that WGS and WES combined with arrays and imputation (WES + IMP) have the largest association yield. Although WGS results in an approximately fivefold increase in the total number of assayed variants over WES + IMP, the number of detected signals differed by only 1% for both single-variant and gene-based association analyses. Given that WES + IMP typically results in savings of lab and computational time and resources expended per sample, we evaluate the potential benefits of applying WES + IMP to larger samples. When we extend our WES + IMP analyses to 468,169 UK Biobank individuals, we observe an approximately fourfold increase in association signals with the threefold increase in sample size. We conclude that prioritizing WES + IMP and large sample sizes rather than contemporary short-read WGS alternatives will maximize the number of discoveries in genetic association studies.
Acarbose enhances the efficacy of immunotherapy against solid tumours by modulating the gut microbiota
Authors: Shi-Long Zhang, Xin Wang, Qing-Qing Cai, Chen Chen, Zheng-Yan Zhang, Ya-Yun Xu, Meng-Xuan Yang, Qing-An Jia, Yan Wang, Zhi-Ming Wang
Journal: Nature Metabolism (2024)
Integration of variant annotations using deep set networks boosts rare variant association testing
Authors: Brian Clarke, Eva Holtkamp, Hakime Öztürk, Marcel Mück, Magnus Wahlberg, Kayla Meyer, Felix Munzlinger, Felix Brechtmann, Florian R Hölzlwimmer, Jonas Lindner, Zhifen Chen, Julien Gagneur, Oliver Stegle
Journal: Nature Genetics (2024)

Rare genetic variants can have strong effects on phenotypes, yet accounting for rare variants in genetic analyses is statistically challenging due to the limited number of allele carriers and the burden of multiple testing. While rich variant annotations promise to enable well-powered rare variant association tests, methods integrating variant annotations in a data-driven manner are lacking. Here we propose deep rare variant association testing (DeepRVAT), a model based on set neural networks that learns a trait-agnostic gene impairment score from rare variant annotations and phenotypes, enabling both gene discovery and trait prediction. On 34 quantitative and 63 binary traits, using whole-exome-sequencing data from UK Biobank, we find that DeepRVAT yields substantial gains in gene discoveries and improved detection of individuals at high genetic risk. Finally, we demonstrate how DeepRVAT enables calibrated and computationally efficient rare variant tests at biobank scale, aiding the discovery of genetic risk factors for human disease traits.
Damaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health
Authors: Sam M Lockhart, Milan Muso, Ilona Zvetkova, Brian Y H Lam, Alessandra Ferrari, Erik Schoenmakers, Katie Duckett, Jack Leslie, Amy Collins, Beatriz Romartínez-Alonso, John A Tadross, Raina Jia, Eugene J Gardner, Katherine Kentistou, Yajie Zhao, Felix Day, Alexander Mörseburg, Kara Rainbow, Debra Rimmington, Matteo Mastantuoni, James Harrison, Meritxell Nus, Khalid Guma'a, Sam Sherratt-Mayhew, Xiao Jiang, Katherine R Smith, Dirk S Paul, Benjamin Jenkins, Albert Koulman, Maik Pietzner, Claudia Langenberg, Nicholas Wareham, Giles S Yeo, Krishna Chatterjee, John Schwabe, Fiona Oakley, Derek A Mann, Peter Tontonoz, Anthony P Coll, Ken Ong, John R B Perry, Stephen O'Rahilly
Journal: Nature Metabolism (2024)

Abstract Liver X receptor-α (LXRα) regulates cellular cholesterol abundance and potently activates hepatic lipogenesis. Here we show that at least 1 in 450 people in the UK Biobank carry functionally impaired mutations in LXRα, which is associated with biochemical evidence of hepatic dysfunction. On a western diet, male and female mice homozygous for a dominant negative mutation in LXRα have elevated liver cholesterol, diffuse cholesterol crystal accumulation and develop severe hepatitis and fibrosis, despite reduced liver triglyceride and no steatosis. This phenotype does not occur on low-cholesterol diets and can be prevented by hepatocyte-specific overexpression of LXRα. LXRα knockout mice exhibit a milder phenotype with regional variation in cholesterol crystal deposition and inflammation inversely correlating with steatosis. In summary, LXRα is necessary for the maintenance of hepatocyte health, likely due to regulation of cellular cholesterol content. The inverse association between steatosis and both inflammation and cholesterol crystallization may represent a protective action of hepatic lipogenesis in the context of excess hepatic cholesterol.
A foundation model for clinician-centered drug repurposing
Authors: Kexin Huang, Payal Chandak, Qianwen Wang, Shreyas Havaldar, Akhil Vaid, Jure Leskovec, Girish N Nadkarni, Benjamin S Glicksberg, Nils Gehlenborg, Marinka Zitnik
Journal: Nature Medicine (2024)

Drug repurposing-identifying new therapeutic uses for approved drugs-is often a serendipitous and opportunistic endeavour to expand the use of drugs for new diseases. The clinical utility of drug-repurposing artificial intelligence (AI) models remains limited because these models focus narrowly on diseases for which some drugs already exist. Here we introduce TxGNN, a graph foundation model for zero-shot drug repurposing, identifying therapeutic candidates even for diseases with limited treatment options or no existing drugs. Trained on a medical knowledge graph, TxGNN uses a graph neural network and metric learning module to rank drugs as potential indications and contraindications for 17,080 diseases. When benchmarked against 8 methods, TxGNN improves prediction accuracy for indications by 49.2% and contraindications by 35.1% under stringent zero-shot evaluation. To facilitate model interpretation, TxGNN's Explainer module offers transparent insights into multi-hop medical knowledge paths that form TxGNN's predictive rationales. Human evaluation of TxGNN's Explainer showed that TxGNN's predictions and explanations perform encouragingly on multiple axes of performance beyond accuracy. Many of TxGNN's new predictions align well with off-label prescriptions that clinicians previously made in a large healthcare system. TxGNN's drug-repurposing predictions are accurate, consistent with off-label drug use, and can be investigated by human experts through multi-hop interpretable rationales.
Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials
Authors: Georg Lenz, Hervé Tilly, Marita Ziepert, Bettina Altmann, Charles Herbaux, Fabian Frontzek, Maike Nickelsen, Calvin Lee, Jamie Hirata, Deniz Sahin, Saibah Chohan, Connie Lee Batlevi, Mark Yan, Franck Morschhauser, Norbert Schmitz
Journal: Leukemia (2024)
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
Authors: Catherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres, Chan Y Cheah, Michael Roost Clausen, David Cunningham, Wojciech Jurczak, Young Rok Do, Robin Gasiorowski, David John Lewis, Tae Min Kim, Marjolein van der Poel, Michelle Limei Poon, Tatyana Feldman, Kim M Linton, Anna Sureda, Martin Hutchings, Minh H Dinh, Nurgul Kilavuz, David Soong, Thomas Mark, Mariana Sacchi, Tycel Phillips, Pieternella J Lugtenburg
Journal: Leukemia (2024)
The burden of atrial fibrillation in the Asia–Pacific region
Authors: Christopher X Wong, Hung Fat Tse, Eue-Kuen Choi, Tze-Fan Chao, Koichi Inoue, Katrina Poppe, Eugene Tan, Yoga Yuniadi, Erdie Fadreguilan, Sofian Johar, Ngai Yin Chan, Narayan Namboodiri, S Mokaddas Hossain, Huang He, Thoranis Chantrarat, Abdul Raqib Bin Abd Ghani, Narantuya Davaakhuu, Nwe Nwe, Ghazala Irfan, Minh That Ton, Rohan Gunawardena, Prashanthan Sanders
Journal: Nature Reviews Cardiology (2024)
Long-term morbidity and mortality of patients who survived past 30 days from bloodstream infection: A population-based retrospective cohort study
Authors: Anthony D Bai, Nick Daneman, Kevin A Brown, J Gordon Boyd, Sudeep S Gill
Journal: Journal of Infection (2024)

For bloodstream infections (BSI), treatment and research have focused on short term mortality. The objective of this study was to describe the 1-year mortality and morbidity in survivors of bloodstream infection when compared to patients with negative blood cultures.
Water-Soluble AIE Photosensitizer in Short-Wave Infrared Region for Albumin-Enhanced and Self-Reporting Phototheranostics
Authors: Yanzi Xu, Jianyu Zhang, Zhi Wang, Peijuan Zhang, Zichen Zhang, Zhiwei Yang, Jacky W Y Lam, Ryan T K Kwok, Lingjie Meng, Dongfeng Dang, Ben Zhong Tang
Journal: Biomaterials (2024)
Multi-dimensional immunotyping of human NF1-associated peripheral nerve sheath tumors uncovers tumor-associated macrophages as key drivers of immune evasion in the tumor microenvironment
Authors: Lindy Zhang, Alexandre Maalouf, Stavriani C. Makri, Jineta Banerjee, Aditya Suru, Ada J. Tam, Ana Calizo, Kai Pollard, Jiawan Wang, Ludmila Danilova, Maria Ioannou, Adam S. Levin, Carol D. Morris, Daniel S. Rhee, Allan J. Belzberg, Jaishri O. Blakeley, Brian H. Ladle, Drew M. Pardoll, Calixto-Hope G. Lucas, Fausto J. Rodriguez, John M. Gross, Robert A. Anders, Christine A. Pratilas, Nicolas J. Llosa
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas and the leading cause of mortality in individuals with neurofibromatosis type 1 (NF1). Despite many clinical trials, outcomes for patients with MPNST have remained stagnant and most succumb to their disease; thus, novel therapeutic approaches are needed. A better understanding of the MPNST immune ecosystem will aid in the development of strategies to activate the immune system against the tumor. Herein, we profile the tumor immune microenvironment (TIME) in NF1-associated peripheral nerve sheath tumors (PNST) to discover insights on the role that tumor-infiltrating immune cells play in malignant transformation. Experimental design: Utilizing fresh and formalin-fixed, paraffin-embedded tissue from patients diagnosed with NF1-PNST, we dissected the TIME by using immunohistochemistry, multiparameter flow cytometry, and comparative transcriptomic studies. Results: Immunophenotyping confirmed increased immune cells infiltration during malignant progression, with a predominance of infiltrating myeloid cells, particularly CD163+ tumor-associated macrophages (TAM). The T cells within MPNST exhibited signs of tumor activation, characterized by high PD-1 expression. Additionally, MPNST specimens demonstrated elevated levels of immunosuppressive TAM, with heightened PD-L1 expression. The proportion of CD163+ myeloid cells within the TIME correlated with poorer progression free survival. Notably, loss of H3K27 trimethylation correlated with low immune cell infiltration in MPNST. Conclusions: Malignant transformation of NF1-PNST is characterized by an immunosuppressive microenvironment comprising of TAM with high expression of PD-L1, which are associated with inferior outcomes. These findings suggest a clinical potential of immune modulating therapeutics that can unleash an anti-tumor immune response.
Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia
Authors: Andrew J.S. Coats, Stefan D. Anker, Lars H. Lund, Gerasimos Filippatos, Patrick Rossignol, Bertram Pitt, Matthew R. Weir, Mikhail N. Kosiborod, Marco Metra, Michael Böhm, Justin A. Ezekowitz, Antoni Bayes-Genis, Robert J. Mentz, Piotr Ponikowski, Michele Senni, John G.F. Cleland, Assen Goudev, Irakli Khintibidze, Joann Lindenfeld, Bela Merkely, Sandra Waechter, Jeffrey Budden, Amandine Perrin, Javed Butler
Journal: JACC Heart Failure (2024)

For heart failure with reduced ejection fraction (HFrEF), suboptimal use of renin-angiotensin-aldosterone system inhibitors (RAASis), including mineralocorticoid receptor antagonists (MRAs), due to hyperkalemia, may be improved by potassium binders.
Association of Multiple Nonhypertrophic Cardiomyopathy–Related Genetic Variants and Outcomes in Patients With Hypertrophic Cardiomyopathy
Authors: Takashi Hiruma, Shunsuke Inoue, Zhehao Dai, Seitaro Nomura, Toru Kubo, Kenta Sugiura, Atsushi Suzuki, Takeshi Kashimura, Shouji Matsushima, Takanobu Yamada, Takashige Tobita, Manami Katoh, Toshiyuki Ko, Masamichi Ito, Junichi Ishida, Eisuke Amiya, Masaru Hatano, Norifumi Takeda, Eiki Takimoto, Hiroshi Akazawa, Hiroyuki Morita, Junichi Yamaguchi, Takayuki Inomata, Hiroyuki Tsutsui, Hiroaki Kitaoka, Hiroyuki Aburatani, Norihiko Takeda, Issei Komuro
Journal: JACC Heart Failure (2024)

Approximately 10% of hypertrophic cardiomyopathy (HCM) patients have left ventricular systolic dysfunction (end-stage HCM) leading to severe heart-failure; however, risk stratification to identify patients at risk of progressing to end-stage HCM remains insufficient.
Diffuse Interstitial Fibrosis of the Myocardium Predicts Outcome in Moderate and Asymptomatic Severe Aortic Stenosis
Authors: Hyun-Jung Lee, Anvesha Singh, Jaehyun Lim, Neil Craig, Rong Bing, Lionel Tastet, Jun-Bean Park, Hyung-Kwan Kim, Yong-Jin Kim, Marie-Annick Clavel, Bernhard L Gerber, Gerry P McCann, Marc R Dweck, Phillipe Pibarot, Seung-Pyo Lee
Journal: JACC. Cardiovascular imaging (2024)